Successful treatment with osimertinib and its subsequent resistance mechanism in a patient with non-small-cell lung cancer harboring acquired EGFR T790M mutation after recovery from AC0010-induced interstitial lung disease

OBJECTIVE: Treatment with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs)can occasionally lead to interstitial lung disease (ILD), and the appropriate treatment after recovery from ILD remains controversial. AC0010 is an investigational third-generation TKI used in China to s...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Hanping, Zhang, Li, Shi, Xiaohua, Zhang, Xiaotong, Si, Xiaoyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6628610/
https://www.ncbi.nlm.nih.gov/pubmed/31371992
http://dx.doi.org/10.2147/OTT.S204689

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6628610/
https://www.ncbi.nlm.nih.gov/pubmed/31371992
http://dx.doi.org/10.2147/OTT.S204689

Ejemplares similares